SEP 2017

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link:

Contents of this Issue


Page 70 of 76

NEWS & EVENTS 68 SEPTEMBER 2017 | Med Esthetics and Keller Funnel is that product for breast augmentation and reconstruction procedures," said David Moatazedi, senior vice president of medical aesthetics, Allergan. "The Keller Funnel was developed and designed by pioneering surgeons to improve breast implantation, and reduce the risks of implant contamination during procedures. This is a natural complement to our world-class plastic surgery and regenerative medicine business, and marketing this innovative device further enhances our commitment to our customers and patients." VA LEA NT TO SELL OBAGI M EDICA L PRODUCTS Valeant Pharmaceuticals has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I. Valeant will use proceeds from the sale to perma- nently repay term loan debt under its Senior Secured Credit Facility. The transaction is expected to close in the second half of 2017, subject to customary closing conditions, includ- ing receipt of applicable regulatory approvals. "The sale of Obagi marks additional progress in our efforts to streamline our operations and reduce debt," said Joseph C. Papa, chairman and CEO of Valeant. "As we continue to transform Valeant, we will remain focused on the core busi- nesses that will drive high value for our shareholders." MOR E TH A N ON E TH I R D OF U.S. CONSU M ERS CONSI DER I NG COSM ETIC EN H A NCEM ENT Nearly 70% of U.S.-based consumers are considering a cos- metic treatment, according to survey data released today by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer Survey on Cosmetic Dermatologic Proce- dures included data gathered through a blind online survey conducted from April 14 – May 1, 2017 with 7,322 responses. Survey takers were asked whether they would consider cosmetic treatments, what they would look for in a provider and what bothers them most about their appearance. Excess body fat was the No. 1 concern (85%) followed by lines and wrinkles around the eyes (70%). Reasons for seeking treatment included: "to feel more confi dent" followed by "to look as young as I feel/better for my age" and "to feel more attractive." The top four procedures consumers are con- sidering are body sculpting (58%), lasers and energy-based treatments (57%), microdermabrasion (53%) and laser hair removal (47%). DEM AND FOR COSMETIC PROCEDURES INCREASING WORLDWIDE The International Society of Aesthetic Plastic Surgery (ISAPS) has released the results of its annual Global Aesthetic Survey for 2016. The United States ranked No. 1 for total number of cosmetic procedures performed followed by Brazil, Japan, Italy and Mexico. The top fi ve countries accounted for 41.4% of cosmetic procedures performed worldwide. Demand for surgical procedures increased 8% from 2015 to 2016 and demand for non-surgical cosmetic enhance- ment increased 10%. The top fi ve non-surgical treatments in 2016 were: • Botulinum toxin injections with 4,931,577 performed worldwide; 1,118,370 of which were in the U.S. • Hyaluronic acid fi ller injections with 3,372,445 per- formed worldwide; 650,232 of which were in the U.S. • Laser hair reduction with 1,146,523 procedures per- formed worldwide; 166,254 of which were in the U.S. • IPL Photorejuvenation with 623,243 procedures per- formed worldwide; 154,770 of which were in the U.S. • Chemical peels with 585,614 performed worldwide; 105,138 of which were in the U.S. The most popular surgical procedures included: breast augmentation, which accounted for 15.8% of all surgical procedures, followed by liposuction (14%), eyelid surgery (12.9%), rhinoplasty (7.6%) and abdominoplasty (7.4%). ISAPS sent questionnaires to 35,000 plastic surgeons to gather data for its global survey. Full results of the survey can be viewed at N ITR IC OX I DE-BASED ACN E TR EATM ENT EFFECTI V E I N A DOLESCENTS Novan Pharmaceutical's SB204, an investigational once- daily, topical nitric oxide-based monotherapy for the treat- ment of acne vulgaris, showed superior efficacy to placebo and a high level of safety in a phase 3 pivotal trial focused on adolescent use. The company presented pharmacokinetic, safety and effi cacy data from the trial at the 13 th World Congress of Pediatric Dermatology in Chicago in June. In the two replicate, multi-center, randomized, double-blinded, vehicle-controlled, parallel group trials, a total of 2,639 patients ages 9 and older with moderate to severe acne were enrolled across 110 sites in the United States. Overall results showed a statistically signifi cant reduction in infl am- matory, non-infl ammatory and total lesion with SB204 4% compared to vehicle, while maintaining a favorable safety and tolerability profi le. "It is encouraging to see a potential new therapy, with positive data, in development for the treatment of acne in adolescents," said Diane Thiboutot, MD, of The Milton S. Hersey Medical Center in Hersey, Pennsylvania, and pro- fessor of dermatology at the Pennsylvania State University College of Medicine. "Acne is one of the most common skin conditions in children and teenagers, and its reach is far beyond the physical effects of the disease, extending to

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - SEP 2017